The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design
- PMID: 18322034
- PMCID: PMC2268283
- DOI: 10.1128/MMBR.00020-07
The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design
Abstract
Enormous efforts have been made to produce a protective vaccine against human immunodeficiency virus type 1; there has been little success. However, the identification of broadly neutralizing antibodies against epitopes on the highly conserved membrane-proximal external region (MPER) of the gp41 envelope protein has delineated this region as an attractive vaccine target. Furthermore, emerging structural information on the MPER has provided vaccine designers with new insights for building relevant immunogens. This review describes the current state of the field regarding (i) the structure and function of the gp41 MPER; (ii) the structure and binding mechanisms of the broadly neutralizing antibodies 2F5, 4E10, and Z13; and (iii) the development of an MPER-targeting vaccine. In addition, emerging approaches to vaccine design are presented.
Figures


Similar articles
-
Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.J Virol. 2005 Jan;79(2):1252-61. doi: 10.1128/JVI.79.2.1252-1261.2005. J Virol. 2005. PMID: 15613352 Free PMC article.
-
Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.Virology. 2008 Mar 30;373(1):72-84. doi: 10.1016/j.virol.2007.11.005. Epub 2007 Dec 26. Virology. 2008. PMID: 18155743 Free PMC article.
-
An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.J Virol. 2007 Apr;81(8):4033-43. doi: 10.1128/JVI.02588-06. Epub 2007 Feb 7. J Virol. 2007. PMID: 17287272 Free PMC article.
-
The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.Protein Cell. 2018 Jul;9(7):596-615. doi: 10.1007/s13238-018-0534-7. Epub 2018 Apr 17. Protein Cell. 2018. PMID: 29667004 Free PMC article. Review.
-
Progress towards the development of a HIV-1 gp41-directed vaccine.Curr HIV Res. 2004 Apr;2(2):193-204. doi: 10.2174/1570162043484933. Curr HIV Res. 2004. PMID: 15078183 Review.
Cited by
-
Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.J Immunol. 2013 Aug 1;191(3):1260-75. doi: 10.4049/jimmunol.1300770. Epub 2013 Jul 3. J Immunol. 2013. PMID: 23825311 Free PMC article.
-
Short Communication: A Recombinant Variant with Increased Envelope Entry Efficiency Emerged During Early Infection of an HIV-1 Subtype C Dual Infected Rapid Progressor.AIDS Res Hum Retroviruses. 2016 Mar;32(3):303-10. doi: 10.1089/AID.2014.0100. Epub 2015 May 20. AIDS Res Hum Retroviruses. 2016. PMID: 25905681 Free PMC article. Clinical Trial.
-
Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.J Virol. 2015 May;89(10):5264-75. doi: 10.1128/JVI.00129-15. Epub 2015 Feb 11. J Virol. 2015. PMID: 25673728 Free PMC article.
-
Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.Nat Microbiol. 2018 Jun;3(6):670-677. doi: 10.1038/s41564-018-0157-z. Epub 2018 May 7. Nat Microbiol. 2018. PMID: 29736037 Free PMC article.
-
New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.NPJ Vaccines. 2020 May 18;5(1):41. doi: 10.1038/s41541-020-0190-9. eCollection 2020. NPJ Vaccines. 2020. PMID: 32435515 Free PMC article.
References
-
- Agarwal, A., S. Sarkar, C. Nazabal, G. Balasundaram, and K. V. Rao. 1996. B cell responses to a peptide epitope. I. The cellular basis for restricted recognition. J. Immunol. 1572779-2788. - PubMed
-
- Alam, S. M., M. McAdams, D. Boren, M. Rak, R. M. Scearce, F. Gao, Z. T. Camacho, D. Gewirth, G. Kelsoe, P. Chen, and B. F. Haynes. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 1784424-4435. - PMC - PubMed
-
- Alam, S. M., R. M. Scearce, R. Parks, K. Plonk, S. G. Plonk, L. L. Sutherland, M. K. Gorny, S. Zolla-Pazner, S. Vanleeuwen, M. A. Moody, S.-M. Xia, D. C. Montefiori, G. D. Tomaras, K. J. Weinhold, S. A. Karim, C. B. Hicks, H.-X. Liao, J. Robinson, G. M. Shaw, and B. F. Haynes. 2008. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82115-125. - PMC - PubMed
-
- Alfsen, A., and M. Bomsel. 2002. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J. Biol. Chem. 27725649-25659. - PubMed
-
- Alfsen, A., P. Iniguez, E. Bouguyon, and M. Bomsel. 2001. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol. 1666257-6265. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources